The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Akhmedov V.A.

Omsk State Medical Academy, Ministry of Health of Russia, Omsk, Russia

Gaus O.V.

Omsk State Medical University, Ministry of Health of Russia, Omsk, Russia

Involvement of the hepatobiliary system and pancreas in obesity

Authors:

Akhmedov V.A., Gaus O.V.

More about the authors

Journal: Therapeutic Archive. 2017;89(1): 128‑133

DOI: 10.17116/terarkh2017891128-133

Read: 8034 times

Download PDF (RU)
Contact the author
Table of contents

INVOLVEMENT OF THE HEPATOBILIARY SYSTEM AND PANCREAS IN OBESITY
INVOLVEMENT OF THE HEPATOBILIARY SYSTEM AND PANCREAS IN OBESITY

To cite this article:

Akhmedov VA, Gaus OV. Involvement of the hepatobiliary system and pancreas in obesity. Therapeutic Archive. 2017;89(1):128‑133. (In Russ.)
https://doi.org/10.17116/terarkh2017891128-133

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Comparative analysis of the state of the microvasculature of the oral mucosa in persons with meta­bolic syndrome in the aspect of orthopedic dental reha­bilitation. Stomatology. 2024;(6-2):15-22
Rela­tionship between meta­bolic syndrome components and pathology of the red border of the lips and oral mucosa. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(4-2):58-63
Chro­nic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medi­cine. 2025;(1):115-121
Identification of prognostic significant markers of early diagnosis of obesity and meta­bolic diso­rders. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):71-79
Effe­ctiveness of using preventive and personalized technologies for obesity correction. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(6-2):80-90
Lapa­roendoscopic hybrid treatment of a patient with choledocholithiasis, cholecystitis and large duodenal dive­rticula. Piro­gov Russian Journal of Surgery. 2025;(1):62-67
Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chro­nic heart failure combined with obesity. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(1):53-60
Safety asse­ssment of bariatric surgery in the Russian Fede­ration acco­rding to the Russian National Bariatric Regi­stry. Endo­scopic Surgery. 2025;(1):5-14
Adipocytokines as a predictor of the risk of adve­rse outcomes in patients with coro­nary heart disease and abdo­minal obesity after percutaneous coro­nary inte­rvention. Russian Journal of Preventive Medi­cine. 2025;(2):38-45
Characteristics of the myocardial stru­ctural and functional para­meters depe­nding on the meta­bolic phenotype of the Arkhangelsk city resi­dents. Russian Journal of Preventive Medi­cine. 2025;(2):53-60
Abstract:

The article provides an overview of current views on the involvement of the liver, gallbladder, and pancreas in patients with overweight and obesity. It considers the general issues of the pathogenesis of these conditions, their clinical features and diagnostic methods.

Keywords:

obesity
metabolic syndrome
insulin resistance
nonalcoholic fatty liver disease
gallbladder cholesterosis
cholelithiasis
pancreatic lipomatosis

Authors:

Akhmedov V.A.

Omsk State Medical Academy, Ministry of Health of Russia, Omsk, Russia

Gaus O.V.

Omsk State Medical University, Ministry of Health of Russia, Omsk, Russia

Close metadata

References:

  1. Lam DW, LeRoith D. Metabolic Syndrome. South Dartmouth (MA): MDText.com; 2015.
  2. Consensus Russian experts on the problem of metabolic syndrome in the Russian Federation: definition, diagnostic criteria for primary prevention and treatment. Rational pharmacotherapy in cardiology. 2010;6(4):599-660. (In Russ.)
  3. Hui WS, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. Eur J Epidemiol. 2010;25(6):375-384. doi:10.1007/s10654-010-9459-z
  4. Duvnjak L, Duvnjak M. The metabolic syndrome — an ongoing story. J Physiol Pharmacol. 2009;60(7):19-24.
  5. Prasenjit Manna, Sushil K Jain. Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies. Metab Syndrome Related Disorders. 2015;13(10):423-444. doi:10.1089/met.2015.0095
  6. Papandreou C, Tuomilehto H. Coronary heart disease mortality in relation to dietary, lifestyle and biochemical risk factors in the countries of the Seven Countries Study: a secondary dataset analysis. J Hum Nutrit Diete. 2014;27(2):168-175. doi:10.1111/jhn.12187
  7. Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59(7):635-643. doi:10.1016/j.jacc.2011.08.080
  8. Millar SR, Perry IJ, Phillips CM. Assessing cardiometabolic risk in middle-aged adults using body mass index and waist-height ratio: are two indices better than one? A cross-sectional study. Diabetol Metab Syndrom. 2015;7:73. doi:10.1186/s13098-015-0069-5
  9. Lazebnyk L, Zvenigorodskaya L, Egorova E. Metabolic syndrome in patients with digestive diseases. Therapeutic Archives. 2007;10(79):9-13. (In Russ.)
  10. Diagnosis and treatment of nonalcoholic fatty liver disease: guidelines for physicians. Edited by Ivashkin V. Moscow: MEDpress-inform; 2012. (In Russ.)
  11. Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015. World J Hepatol. 2015;7(30):2962-2967. doi:10.4254/wjh.v7.i30.2962
  12. Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. World Gastroenterology Organisation Global Guidelines. June, 2012. Accessed January 18, 2016. Available at: http://www.worldgastroenterology.org/NAFLD-NASH.html
  13. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55:2005-2023. doi:10.1002/hep.25762
  14. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease — current status and future directions. J Digest Dis. 2015;16(10):541-557. doi:10.1111/1751-2980.12291
  15. Yu SJ, Kim W, Kim D, Yoon JH, Lee K, Kim JH, Cho EJ, Lee JH, Kim HY, Kim YJ, Kim CY. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2015;94(48):e2159.
  16. Gaus O, Akhmedov V. Dynamic of clinical, laboratory and sonographic parameters after successful litholytic therapy in patients with cholelithiasis in association with metabolic syndrome. Experimental and clinical gastroenterology. 2015;7(119 ):18-23. (In Russ.)
  17. Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:394-402.e. doi:10.1016/j.cgh.2013.09.023
  18. Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. J Hepatol. 2013;57:1357-1365. doi:10.1002/hep.26156
  19. Kawada T. Liver fat, visceral fat and metabolic syndrome in patients with severe obesity. Int J Surg. 2015;22:153-158. doi:10.1016/j.ijsu.2015.09.001
  20. Yuan L, Bambha K. Bile acid receptors and nonalcoholic fatty liver disease. World J Hepatol. 2015;7(28):2811-2818. doi:10.4254/wjh.v7.i28.2811
  21. Dobson R, Burgess MI, Sprung VS, Irwin A, Hamer M, Jones J, Daousi C, Adams V, Kemp GJ, Shojaee-Moradie F, Umpleby M, Cuthbertson DJ. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes. 2015;40(1):153-161. doi:10.1038/ijo.2015.151
  22. Komshilova K, Troshina E. Obesity and non-alcoholic fatty liver disease: metabolic risks and their correction. Obesity and Metabolism. 2015;2(12):35-39. (In Russ.)
  23. Komshilova K, Troshina E, Ershov E, Mazurina N, Platonova N. Adiponectin and glucose metabolism and lipid indicators in different clinical and morphological stages of nonalcoholic fatty liver disease in patients with abdominal obesity. Therapeutic Archives. 2014;10:27-32. (In Russ.)
  24. Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D, Vlahovic-Palcevski V, Orlic L. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Design, Development and Therapy. 2015;9:4835-4845. doi:10.2147/DDDT.S64877
  25. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174-1197. doi:10.1002/hep.26717
  26. Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(24):7427-7435. doi:10.3748/wjg.v21.i24.7427
  27. Lazebnyk L, Radchenko V, Golovanova E, Zvenigorodskaya L, Konev Y, Seliverstov P, Sitkin S, Tkachenko E, Ailamazyan E, Vlasov N, Kornienko E, Novikova V, Horoshinina L, Zhestkova N, Oreshko L, Dudanova O, Dobrica V, Tureva L, Tirikova O, Kozlova N et al. Non-alcoholic fatty liver disease: clinical features, diagnosis, treatment recommendations approved by the XV Congress NSGR in 2015. Experimental and clinical gastroenterology. 2015;7(119):85-96. (In Russ.)
  28. Komshilova K, Troshina E. Obesity and non-alcoholic fatty liver disease. Treatment and prevention. 2012;1:99-108. (In Russ.)
  29. Sheptulina A, Shirokova E, Ivashkin V. Non-invasive diagnosis of liver fibrosis: role of serum markers. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;2(25):28-40. (In Russ.)
  30. Maiev I, Kuznetsova E, Andreev D, Dicheva D. Current and future approaches to the diagnosis of non-alcoholic fatty liver disease. Consilium Medicum. 2015;8(17):20-27. (In Russ.)
  31. Pereira K, Salsamendi J, Casillas J. The global nonalcoholic fatty liver disease epidemic: what a radiologist needs to know. J Clin Imag Scie. 2015;5:32. doi:10.4103/2156-7514.157860
  32. Zvenigorodskaya L, Ovsyannikov O. Steatogepatit and cholesterosis of gallbladder in patients with metabolic syndrome. Difficult patient. 2010;3(8):54-58. (In Russ.)
  33. Chen L-Y, Qiao Q-H, Zhang S-C, Chen Y-H, Chao G-Q, Fang L-Z. Metabolic syndrome and gallstone disease. World J Gastroenterol. 2012;18:4215-4220. doi:10.3748/wjg.v18.i31.4215
  34. Ilchenko A. Diseases of the gallbladder and bile ducts. Hand-in for doctors 2nd edition. Moscow: Medical News Agency; 2011. (In Russ.)
  35. Lim SH, Kim D, Kang JH, Song JH, Yang SY, Yim JY, Chung SJ, Kim JS, Cho SH. Hepatic fat, not visceral fat, is associated with gallbladder polyps: a study of 2643 healthy subjects. J Gastroenterol Hepatol. 2015;30(4):767-774. doi:10.1111/jgh.12841
  36. Yang HL, Kong L, Hou LL, et al. Analysis of risk factors for polypoid lesions of gallbladder among health examinees. J Gastroenterol Hepatol. 2012;18:3015-3019. doi:10.3748/wjg.v18.i23.3015
  37. Lee JK, Hahn SJ, Kang HW, Jung JG, Choi HS, Lee JH, Han IW, Jung JH, Kwon JH. Visceral obesity is associated with gallbladder polyps. Gut Liver. 2016;10(1):133-139. doi:10.5009/gnl14506
  38. Park EJ, Lee HS, Lee SH, Chun HJ, Kim SY, Choi YK, Ryu HJ, Shim KW. Association between metabolic syndrome and gallbladder polyps in healthy Korean adults. J Korean Med Scie. 2013;28(6):876-880. doi:10.3346/jkms.2013.28.6.876
  39. Babu BI, Dennison AR, Garcea G. Management and diagnosis of gallbladder polyps: a systematic review. Langenbecks’s Archives of Surgery. 2015;400(4):455-462. doi:10.1007/s00423-015-1302-2
  40. Song HL, Shin JH, Kim H, Park YL, Yoo CH, Son BH, Yoon JS, Kim HO. Clinical and radiologic preoperative predicting factors for GB cholesterol polyp. J Korean Surg Society. 2012;82(4):232-237. doi:10.4174/jkss.2012.82.4.232
  41. Bagirov R, Troshina T, Chesnokov L, Medvedev I. Cholesterosis gallbladder — an early marker of atherosclerosis in patients with metabolic syndrome. Medical science and education in the Urals. 2012; 1: 7-10. (In Russ.)
  42. Lazebnyk L, Ovsyannikova O, Zvenigorodskaya L, Melnikova N, Samsonova I, Khomeriki S. Cholesterosis gallbladder and atherogenic dislipidemiya: etiology, pathogenesis, clinical manifestations, diagnosis, treatment. Therapeutic Archives. 2008;1(80):57-61. (In Russ.)
  43. Jessri M, Rashidkhani B. Dietary patterns and risk of gallbladder disease: a hospital-based case-control study in adult women. . J Health, Populat Nutrition. 2015;33(1):39-49.
  44. Bueverov A. Chronic diseases of the gallbladder and biliary tract. Quick guide for practitioners. Moscow; 2015. (In Russ.)
  45. Kuliaviene I, Gulbinas A, Cremers J, Pundzius J, Kupcinskas L, Dambrauskas Z, Jansen E. Fatty acids of erythrocyte membrane in acute pancreatitis patients. World J Gastroenterol. 2013;19(34):5678-5684. doi:10.3748/wjg.v19.i34.5678
  46. Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, Chim AM, Shen J, Ho CS, Woo J, Chu WC, Chan HL. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014;109(4):589-597. doi:10.1038/ajg.2014.1
  47. Uygun A, Kadayifci A, Demirci H, Saglam M, Sakin YS, Ozturk K, Polat Z, Karslioglu Y, Bolu E. The effect of fatty pancreas on serum glucose parameters in patients with nonalcoholic steatohepatitis. Eur J Int Med. 2015;26(1):37-41. doi:10.1016/j.ejim.2014.11.007
  48. Della Corte C, Mosca A, Majo F, Lucidi V, Panera N, Giglioni E, Monti L, Stronati L, Alisi A, Nobili V. Nonalcoholic fatty pancreas disease and nonalcoholic fatty liver disease: more than ectopic fat. Clin Endocrinol. 2015;83(5):656-662. doi:10.1111/cen.12862
  49. Batskov C, Pronina G, Inzhevatkin D. Nonalcoholic fatty disease of the pancreas as the digestivе marker of the metabolic syndrome. Medicobiological and sociopsychological problems of safety in emergency situations. 2012;4:50-55. (In Russ.)
  50. Gubergrits N, Bondarenko O. Non-alcoholic fatty disease of the liver and pancreas: frequency of combination. Pancreatology. 2013;13(3):44. doi:10.1016/j.pan.2013.04.147
  51. Pezzilli R, Calculli L. Pancreatic steatosis: Is it related to either obesity or diabetes mellitus? World J Diabet. 2014;5(4):415-419. doi:10.4239/wjd.v5.i4.415
  52. Roever L. Pancreatic steatosis: is it related to obesity, diabetes mellitus and metabolic syndrome? Pancreatic Disorders and Therapy. 2015;5:e139. doi:10.4172/2165-7092.1000e139
  53. Wang CY, Ou HY, Chen MF, Chang TC, Chang CJ. Enigmatic ectopic fat: prevalence of nonalcoholic fatty pancreas disease and its associated factors in a Chinese population. Journal of the American Heart Association. 2014;3(1):e000297. doi:10.1161/JAHA.113.000297
  54. Mirrakhimov AE. Nonalcoholic fatty pancreatic disease and cardio-metabolic risk: is there is a place for obstructive sleep apnea? Cardiovasc Diabetol. 2014;13:29. doi:10.1186/1475-2840-13-29
  55. Wu WC, Wang CY. Association between non-alcoholic fatty pancreas disease and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013;12:77. doi:10.1186/1475-2840-12-77
  56. Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, Seki E, Sirlin CB, Loomba R. Insulin resistance increases MRI-estimated pancreatic fat in nonalcoholic fatty liver disease and normal controls. Gastroenterol Res Pract.. 2013;2013:498296. doi:10.1155/2013/498296
  57. Ou HY, Wang CY, Yang YC, et al. The association between nonalcoholic fatty pancreas disease and diabetes. PLoS One. 2013;8(5):e62561. doi:10.1371/journal.pone.0062561
  58. Ambesh P, Lal H. Pancreatic lipomatosis: complete replacement of pancreas by fat. J Clin Diagn Res. 2015;9(10):OL01. doi:10.7860/JCDR/2015/15085.6653
  59. Li J, Xie Y, Yuan F, Song B, Tang C. Noninvasive quantification of pancreatic fat in healthy male population using chemical shift magnetic resonance imaging: effect of aging on pancreatic fat content. Pancreas. 2011;40(2):295-299. doi:10.1097/MPA.0b013e318201669f
  60. Yasuda M, Niina Y, Uchida M, Fujimori N, Nakamura T, Oono T, Igarashi H, Ishigami K, Yasukouchi Y, Nakamura K, Ito T, Takayanagi R. A case of lipomatous pseudohypertrophy of the pancreas diagnosed by typical imaging. J Pancreas. 2010;11(4):385-388.
  61. Yang RY, Ng D, Jaskolka JD, Rogalla P, Sreeharsha B. Evaluation of percutaneous ultrasound- guided biopsies of solid mass lesions of the pancreas: a center’s 10-year experience. Clin Imag. 2015;39(1):62-65. doi:10.1016/j.clinimag.2014.06.010
  62. Kajor M, Ziaja JL, Kostrzab-Zdebel A, Wlaszczuk P, Karkoszka H, Sekta S, Krol R, Cierpka L. Histopathological examination may be useful for assessment of fibrosis and lipomatosis of pancreas allograft prior to solid organ transplantation. Ann Transplant. 2015;20:655-660. doi:10.12659/AOT.894464
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.